General information, not legal or regulatory advice. Confirm current ethics and national-file rules with qualified advisers. We do not invent clocks, rates, or named studies that are not on the locked public sources cited here. No patient data. No unpublished client. Always bioaccess®.
If you searched Novotech Australia FIH CRO, Novotech first-in-human medical device Australia, Novotech Sydney device EFS, you were looking for a first-in-human / early-feasibility medical-device CRO in Australia. Competitor watch on this cluster is the named AU/IL/CA FIH CRO set only: Avania, Novotech, GreenLight Clinical, Bioforum, JSS Medical Research. We do not invent extra CRO brands. We do not invent extra named sponsors. We do not sell insurance. We do not name a carrier as a signed partner. Nanochon stays HOLD. NextLife is not a new steal. Magical BTK stays off this page. No PHI.
Novotech is a Sydney-founded regional mega-CRO. Device sponsors type the name because Australia-as-country-1 is a slide they have already seen. Honest hedge, locked on 28 Aug 2026 and re-checked 1 Sep 2026: Novotech’s public case-study hub is drug FIH. 2026 pages include a complex GMO oncology trial (AU + US, FPFD 2 Dec 2025), FIH mRNA immunotherapy across APAC, and Phase I/II oncology start-up in Australia for a China biotech (May 2026). Older DiaMedica Phase I is drug. No device case study was found on the hub. This page still exists because the search is real. We will not invent a Novotech device FIH to fill the gap.
This page is not a leftover-site hospital intercept and not an insurance intercept. Distinct slug. Distinct title. The job is country 2: keep Australia if it is already running, add Latin America for the next protocol, the expansion, or the backup geography. Eligibility of foreign data under 21 CFR 812.28 is not FDA clearance. See OUS FIH and FDA IDE.
What this search is actually buying
If you are a drug sponsor, this is the wrong operator. If you are a device sponsor who Googled Novotech because CTN + R&DTI is the Australia story, country 2 is a Latin American hospital-implant stack, not a second Novotech work order we invent. Do not count GMO, mRNA, or DiaMedica toward a device five-trial goal.
What we will not do with Novotech’s named drug FIHs
ReveraGen, PharmAbcine, DiaMedica, Botanix and other names that appear on drug case pages are not medical-device EFS. We will not re-skin them as implants. We will not imply Novotech ran an unnamed stent, valve, or liquid embolic in Australia. If a future public Novotech page names a true device FIH/EFS, that is a later refresh — not this intercept.
Why a device founder still uses this search
Australia-first is sold on speed and incentives. A device still needs ISO 14155, implant or interventional sites, import, and a 21 CFR 812.28 story. A mega-CRO drug Phase I unit is not that. GreenLight Clinical is a different AU CRO intercept. Avania is the AU shop actually publishing device FIH cases. Do not merge the three brands.
Country 2 is LATAM. It is not a second Australian CTN, and it is not a new Colombian FIH CTA
Keep Australia if it is already running. Add Panama, Chile, Brazil, Mexico, or El Salvador for the n that will not wait on another CTN. Do not default to a new Colombian FIH.
Use clinical-trials-panama. Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national file. Ethics review runs through institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). Published ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks on that hub. Per-patient costs there: $12,000–$22,000 in U.S. dollars. A hallway conversation at this hospital is not MINSA clearance.
Use clinical-trials-chile. Instituto de Salud Pública (ISP) authorizes studies and investigational-device import. Live Chile blogs already put a typical ISP review in a band of about 30 business days. Commercial ISP registration in a 30–90 day band is a different file — do not put trial authorization and commercial registro on one Gantt labeled “Chile.” An Ethical-Scientific Committee under Law 20.120 still has to sit. We will not invent PAHO/WHO Level 4 standing for ISP on this page.
Use clinical-trials-brazil: combined ethics + ANVISA typically 6–10 weeks under Law 14874 and RDC 837/2023; CEPs capped at 30 business days; published per-patient range $20,000–$35,000. Trial authorization and later market registration are separate workstreams.
Use clinical-trials-mexico and CRO in Mexico. Ethics typically 4–6 weeks and COFEPRIS review typically 4–8 weeks after ethics on the live Mexico hub; combined start-up is cited there as a 2.8-month median. Keep trial clocks separate from registro sanitario (~30 working days on that hub). Eligibility of foreign data under 21 CFR 812.28 is not a guarantee of clearance.
El Salvador is a public bioaccess® geography (DNM on llms.txt; live hub at clinical-trials-el-salvador). We will not invent a new Salvadoran clock here.
Colombia stays market access
Public line, unchanged: INVIMA commercial medical-device registration remains a core bioaccess® service. Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. Country 2 on this cluster is Panama, Chile, Brazil, Mexico, or El Salvador — not a new Colombian FIH CTA. The Panama country page still publishes ethics 3–5 weeks vs. Colombia 4–6 weeks and per-patient $12K–$22K vs. $15K–$25K. Always bioaccess®. The founder podcast is Global Trial Accelerators™.
Historic Colombia FIH on public bioaccess® pages is not a reason to book a new INVIMA FIH from this cluster. Do not treat a Bogotá hospital NCT row as country 2.
What bioaccess® still owns on the steal
- ISO 14155 field-clinical, not a Phase I unit brochure. Hospital implant and interventional sites in Panama, Chile, Brazil, Mexico, El Salvador as the device needs.
- Protocol, IB, ICF, ethics / national file in the same stack. A hallway conversation at an Australian private hospital is not that file.
- Importer of record and device accountability. See importer of record for clinical trial devices in Latin America. A CTN or Health Canada CTA does not import the investigational product into Latin America.
- 21 CFR 812.28 narrative if the next stop is an FDA IDE. Eligibility of foreign data is not a guarantee of clearance.
- No AU / IL / CA legal entity required to start country 2. Do not wait on R&DTI, a second CTN, or a Toronto MSA to generate the next n.
The firm was founded in 2010. Public device case studies already on llms.txt (ReGelTec, Axoft, Newrotex, enVVeno, Avantec Vascular / Sangria™ as published) show FIH execution. We will not invent a new named client onto this page.
Frequently asked questions
Is bioaccess® trying to replace the incumbent CRO on a live protocol?
No. If Avania, Novotech, GreenLight Clinical, Bioforum, or JSS is already running country 1, the steal is the next protocol, the expansion, or a LATAM satellite — not a mid-study rip-out we invent.
Do you sell clinical trial insurance on this page?
No. We are the FIH CRO. Insurance intercepts live on their own slugs. We do not underwrite. We do not name HDI as a partner here.
Is Colombia the country-2 default?
No. New FIH execution is not the Colombia CTA on this cluster. INVIMA registro remains. See the Colombia paragraph above.
Next step
If the search that brought you here was Novotech Australia as the FIH CRO, start as the operator: contact bioaccess® or book from First-in-Human CRO. Siblings: Avania AU, GreenLight Clinical AU.
Julio G. Martinez-Clark, CEO · bioaccess®